Voyageur Pharmaceuticals Ltd. Share Price OTC Markets
Stocks
VYYRF
CA92918C1014
Pharmaceuticals
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0950 USD | -.--% |
|
-5.00% | -26.98% |
| Market Cap | 29.42M 20.74M 18.12M 16.64M 15.52M 1.97B 29.92M 200M 77.66M 969M 77.88M 76.19M 3.34B | P/E 2024 |
-5.24x | P/E 2025 | -7.5x |
|---|---|---|---|---|---|
| Enterprise Value | 29.19M 20.58M 17.98M 16.51M 15.4M 1.96B 29.69M 199M 77.05M 961M 77.27M 75.59M 3.31B | EV / Sales 2024 |
-
| EV / Sales 2025 | 2,423,581,172x |
| Free-Float |
93.03% | Yield 2024 * |
-
| Yield 2025 | - |
| 1 week | -5.00% | ||
| 1 month | +578.57% | ||
| 3 months | -2.06% | ||
| 6 months | -26.98% | ||
| Current year | -26.98% |
| 1 week | 0.09 | 0.1 | |
| 1 month | 0.02 | 0.2 | |
| Current year | 0.01 | 0.2 | |
| 1 year | 0 | 0.2 | |
| 3 years | 0 | 0.25 | |
| 5 years | 0 | 0.25 | |
| 10 years | 0 | 0.25 |
| Manager | Title | Age | Since |
|---|---|---|---|
Brent Willis
CEO | Chief Executive Officer | - | 30/06/2019 |
| Director of Finance/CFO | - | 16/08/2022 | |
Iryna Saranchova
CTO | Chief Tech/Sci/R&D Officer | - | 16/09/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Jeffrey Kraws
BRD | Director/Board Member | 62 | - |
Brent Willis
BRD | Director/Board Member | - | 05/12/2017 |
Brad Willis
BRD | Director/Board Member | - | 30/06/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -.--% | -5.00% | - | - | 19.92M | ||
| +1.86% | +7.65% | +55.77% | +158.84% | 1,063B | ||
| +3.57% | +7.42% | +69.09% | +58.92% | 611B | ||
| +3.99% | +7.37% | +36.87% | +93.77% | 444B | ||
| -1.20% | -0.96% | +26.12% | +20.22% | 324B | ||
| +4.94% | +4.51% | +39.76% | +28.93% | 285B | ||
| +2.42% | +2.96% | +30.77% | +42.24% | 283B | ||
| +2.47% | +6.56% | -24.26% | -39.60% | 219B | ||
| +3.55% | +6.05% | +26.04% | +68.52% | 195B | ||
| +4.21% | +6.00% | +17.72% | +70.33% | 156B | ||
| Average | +2.11% | +2.83% | +30.88% | +55.80% | 397.85B | |
| Weighted average by Cap. | +1.85% | +4.16% | +41.60% | +80.68% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | - | 0.01 0.01 0.01 0.01 0.01 0.78 0.01 0.08 0.03 0.38 0.03 0.03 1.33 |
| Net income | -1.71M -1.2M -1.05M -966K -901K -115M -1.74M -11.63M -4.51M -56.2M -4.52M -4.42M -194M | -3.53M -2.49M -2.18M -2M -1.86M -237M -3.59M -24.06M -9.32M -116M -9.35M -9.15M -401M |
| Net Debt | -113K -79.4K -69.38K -63.71K -59.41K -7.56M -115K -767K -297K -3.71M -298K -292K -12.78M | -231K -163K -142K -130K -122K -15.47M -234K -1.57M -609K -7.59M -610K -597K -26.15M |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/06/26 | US$0.0950 | -.--% | 7,080 |
| 29/06/26 | US$0.0950 | +7.71% | 2,920 |
| 26/06/26 | US$0.0882 | -11.80% | 36,000 |
Annual profits - Rate of surprise
- Stock Market
- Stocks
- VM Stock
- VYYRF Stock
Select your edition
All financial news and data tailored to specific country editions
















